In short
BI 765845 is a new medication currently being studied in clinical trials to help people who have recently experienced a heart attack. These trials aim to evaluate the drug's effectiveness, safety, and how well it is tolerated by patients. The studies involve both heart attack patients and healthy volunteers to gather comprehensive data on the drug's potential benefits and side effects.
At a glance
- Drug Name
- BI 765845
- Main Condition Studied
- Myocardial Infarction (Heart Attack)
- Administration Method
- Intravenous (through a vein)
- Main Trial Duration
- 3 months
- Primary Outcome Measure
- Infarct size (percentage of damaged left ventricular mass)
- Imaging Technique
- Cardiac Magnetic Resonance (CMR) with Late Gadolinium Enhancement (LGE)
- Additional Studies
- Safety and pharmacokinetics in healthy volunteers
What is BI 765845?
BI 765845 is a new investigational drug being developed to help people who have recently experienced a heart attack, also known as a myocardial infarction. A heart attack occurs when blood flow to a part of the heart is blocked, usually by a blood clot, causing damage to the heart muscle. This medication is currently undergoing clinical trials to assess its effectiveness and safety in treating patients who have suffered from this serious cardiovascular event.
How Does BI 765845 Work?
While the exact mechanism of action is not explicitly stated in the provided information, BI 765845 is being studied for its potential to reduce infarct size. Infarct size refers to the amount of heart muscle damaged during a heart attack. By potentially reducing this damage, BI 765845 may help improve outcomes for heart attack patients.
Clinical Trials
BI 765845 is currently being evaluated in several clinical trials:
- IRI-EXPLORE Study: This is a large-scale trial involving adults aged 18 and over who have recently had a heart attack. The study aims to test different doses of BI 765845 and assess how well they work compared to a placebo.
- Japanese Safety Study: This trial focuses on testing the safety, tolerability, and pharmacokinetics (how the drug moves through the body) of BI 765845 in healthy Japanese men.
- General Safety Study: This study investigates the safety, tolerability, and pharmacokinetics of BI 765845 in healthy male subjects and female subjects who cannot bear children.
Potential Benefits
The main potential benefit of BI 765845 is its ability to reduce the size of the damaged area in the heart after a heart attack. Researchers are measuring this by looking at the percentage of left ventricular mass that is infarcted (damaged) using a special imaging technique called late gadolinium enhancement (LGE) by cardiac magnetic resonance (CMR). If successful, this could lead to better recovery and outcomes for heart attack patients.
Safety and Tolerability
A significant focus of the ongoing clinical trials is to assess the safety and tolerability of BI 765845. Researchers are carefully monitoring for any treatment-emergent adverse events (side effects that occur during treatment) and how they relate to the drug. This information will help determine the optimal dosage and identify any potential risks associated with the medication.
Administration
Based on the information provided, BI 765845 is administered intravenously (through a vein). The trials are testing various doses and treatment regimens to determine the most effective and safe approach for patients.
Future Prospects
As BI 765845 is still in the clinical trial phase, it is not yet available for general use. The results of these studies will determine whether the drug is effective and safe enough to be approved for treating heart attack patients. If successful, BI 765845 could become an important addition to the standard of care for individuals who have experienced a heart attack, potentially improving their recovery and long-term outcomes.